Loading clinical trials...
Loading clinical trials...
VALENS: A Phase 1/2, Randomized, Open-Label, Ascending-Dose, Delayed-Treatment Concurrent Control Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT342, an AAV8-Delivered Gene Transfer Therapy in Crigler-Najjar Syndrome Subjects Aged 1 Year and Older
Conditions
Interventions
AT342
Locations
4
United States
Children's Hospital at Montefiore
The Bronx, New York, United States
Clinic for Special Children
Strasburg, Pennsylvania, United States
Shaare Zedek Medical Center
Jerusalem, Israel
King's College Hospital NHS Foundation Trust
London, United Kingdom
Start Date
September 8, 2017
Primary Completion Date
February 11, 2021
Completion Date
February 11, 2021
Last Updated
May 18, 2022
Lead Sponsor
Audentes Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions